REGENXBIO RGNX 深 滬
等待開盤 09-30 09:30:00 美东时间
9.85
+0.200
+2.07%
華盛通- 最 高10.17
- 今 開9.74
- 成交量 70.66万股
- 最 低 9.68
- 昨 收 9.65
- 總市值 4.98亿
- 52周最高 12.22
- 市盈率 靜 --
- 換手率 1.40%
- 52周最低 5.035
- 委 比 -46.43%
- 總股本 5051.42万
- 歷史最高 85.10
- 量 比 1.44
- 振 幅 5.08%
- 歷史最低 5.035
- 每 手 1
- 風險率 3.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多REGENXBIO To Present RGX-202 Phase I/II Functional Data At WMS 2025; Highlights NSAA Gains, Favorable Safety Profile Vs. Natural History Controls
REGENXBIO Inc. (NASDAQ: RGNX) today announced Chief Medical Officer, Steve Pakola, M.D., will present at the International Congress of the World Muscle Society taking place in Vienna, Austria, October 7-11, 2025.
09-29 19:18
REGENXBIO Announces Presentation at the World Muscle Society
ROCKVILLE, Md., Sept. 29, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced Chief Medical Officer, Steve Pakola, M.D., will present at the International Congress of the Worl...
09-29 19:05
REGENXBIO reports positive data from Hunter syndrome
REGENXBIO (NASDAQ:RGNX) reported positive results from its trial investigating the gene therapy, clemidsogene lanparvovec (RGX-121), for Hunter syndrome treatment. In the 12-month pivotal trial involv...
09-05 21:42
REGENXBIO Announces Data From Phase I/II/III CAMPSIITE Trial Of Clemidsogene Lanparvovec For Treatment Of Patients With Mucopolysaccharidosis Type II At ICIEM 2025
12-month pivotal data further demonstrate the ability of one-time RGX-121 treatment to improve outcomes for patients with MPS II>80% reduction in CSF levels of HS D2S6, key biomarker of MPS II brain disease, sustained
09-05 19:08
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. has granted 113,572 restricted stock units to 33 newly hired non-executive officers under the Ultragenyx Employment Inducement Plan, with a grant date of August 16, 2025. The awards, approved by the company's compensation committee, vest over four years, with 25% of shares vesting annually contingent on continuous employment. Ultragenyx, a biopharmaceutical company focused on developing therapies for rare and ultra-...
08-21 21:00
Analyst Expectations For Regenxbio's Future
Across the recent three months, 5 analysts have shared their insights on Regenx...
08-19 20:00
Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
Ultragenyx Pharmaceutical Inc. announced the initiation of a rolling submission of a Biologics License Application (BLA) to the FDA for DTX401 AAV gene therapy, intended to treat Glycogen Storage Disease Type Ia (GSDIa). The company has already submitted non-clinical and clinical modules and plans to complete the full BLA, including the chemistry, manufacturing, and controls (CMC) module, by the fourth quarter of 2025. The BLA includes 96-week da...
08-18 12:00
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
Chardan Capital Maintains Buy on Regenxbio, Maintains $52 Price Target
Chardan Capital analyst Daniil Gataulin maintains Regenxbio (NASDAQ:RGNX) with a Buy and maintains $52 price target.
08-08 20:10
RegenXBio and AbbVie Amend Collaboration Agreement
RegenXBio ( ($RGNX) ) has shared an update. On August 5, 2025, REGENXBIO Inc. a...
08-07 19:54
